The development of antibody-IL-2 based immunotherapy with hu14.18-IL2 (EMD-273063) in melanoma and neuroblastoma

Bibliography

• Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2007. CA Cancer J Clin 2007;57:43-66
   PubMed Web of Science ®Google Scholar
• Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2008. CA Cancer J Clin 2008;58:71-96
   PubMed Web of Science ®Google Scholar
• Kirkwood JM, Ibrahim JG, Sosman JA, et al. High-dose interferon alfa-2b significantly prolongs relapse-free and overall survival compared with the GM2-KLH/QS-21 vaccine in patients with resected stage IIB-III melanoma: results of intergroup trial E1694/S9512/C509801. J Clin Oncol 2001;19:2370-80
   PubMed Web of Science ®Google Scholar
• Sondel PM, Hank JA, Albertini MR, Gillies SD. Novel strategies for cytokine administration via targetting. In: Caligiuri MA, Lotze MT, editors, Cancer Drug Discovery and Development, Cytokines in the Genesis and Treatment of Cancer. Totowa, NJ: Humana Press Inc; 2008
   Google Scholar
• Phan GQ, Yang JC, Sherry RM, et al. Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma. Proc Natl Acad Sci USA 2003;100:8372-7
   PubMed Web of Science ®Google Scholar
• Camacho LH, Antonia S, Sosman J, et al. Phase I/II trial of tremelimumab in patients with metastatic melanoma. J Clin Oncol 2009;27:1075-81
   PubMed Web of Science ®Google Scholar
• Spitler LE, Grossbard ML, Ernstoff MS, et al. Adjuvant therapy of stage III and IV malignant melanoma using granulocyte-macrophage colony-stimulating factor. J Clin Oncol 2000;18:1614-21
   PubMed Web of Science ®Google Scholar
• Kirkwood JM, Lee S, Moschos SJ, et al. Immunogenicity and antitumor effects of vaccination with peptide vaccine+/-granulocyte-monocyte colony-stimulating factor and/or IFN-alpha2b in advanced metastatic melanoma: Eastern Cooperative Oncology Group Phase II Trial E1696. Clin Cancer Res 2009;15:1443-51
   PubMed Web of Science ®Google Scholar
• Brodeur GM. Significance of intratumoral genetic heterogeneity in neuroblastomas. Med Pediatr Oncol 2002;38:112-3
   PubMedGoogle Scholar
• Ries LAG, et al. SEER Cancer Statistics Review, 1975-2004,National Cancer Institute. Bethesda, MD, http://seer.cancer.gov/csr/1975_2004/, based on November 2006 SEER data submission, posted to the SEER Web site, 2007. 2007
   Google Scholar
• Matthay KK, Villablanca JG, Seeger RC, et al. Treatment of high-risk neuroblastoma with intensive chemotherapy, radiotherapy, autologous bone marrow transplantation, and 13-cis-retinoic acid. Children's Cancer Group. N Engl J Med 1999;341:1165-73
   PubMed Web of Science ®Google Scholar
• American Cancer Society. Cancer Facts and Figures. 2004. Atlanta, GA, ACS publications
   Google Scholar
• Mujoo K, Cheresh DA, Yang HM, Reisfeld RA. Disialoganglioside GD2 on human neuroblastoma cells: target antigen for monoclonal antibody-mediated cytolysis and suppression of tumor growth. Cancer Res 1987;47:1098-104
   PubMed Web of Science ®Google Scholar
• Cheung NK, Saarinen UM, Neely JE, et al. Monoclonal antibodies to a glycolipid antigen on human neuroblastoma cells. Cancer Res 1985;45:2642-9
   PubMed Web of Science ®Google Scholar
• Chang HR, Cordon-Cardo C, Houghton AN, et al. Expression of disialogangliosides GD2 and GD3 on human soft tissue sarcomas. Cancer 1992;70:633-8
   PubMed Web of Science ®Google Scholar
• Sondel PM, Hank JA. Antibody-directed, effector cell-mediated tumor destruction. Hematol Oncol Clin North Am 2001;15:703-21
   PubMed Web of Science ®Google Scholar
• Yoshida S, Kawaguchi H, Sato S, et al. An anti-GD2 monoclonal antibody enhances apoptotic effects of anti-cancer drugs against small cell lung cancer cells via JNK (c-Jun terminal kinase) activation. Jpn J Cancer Res 2002;93:816-24
   PubMedGoogle Scholar
• Johnson E, Dean SM, Sondel PM. Antibody-based immunotherapy in high-risk neuroblastoma. Expert Rev Mol Med 2007;9:1-21
   PubMedGoogle Scholar
• Svennerholm LBK, Fredman P, Jungbjer B, et al. Gangliosides and allied glycosphingolipids in human peripheral nerve and spinal cord. Biochim Biophys Acta 1994;1214:115-23
   PubMed Web of Science ®Google Scholar
• Mueller BM, Romerdahl CA, Gillies SD, Reisfeld RA. Enhancement of antibody-dependent cytotoxicity with a chimeric anti-GD2 antibody. J Immunol 1990;144:1382-6
   PubMed Web of Science ®Google Scholar
• Berd D, Herlyn M, Koprowski H, Mastrangelo MJ. Flow cytometric determination of the frequency and heterogeneity of expression of human melanoma-associated antigens. Cancer Res 1989;49:6840-4
   PubMed Web of Science ®Google Scholar
• Schengrund CL, Repman MA, Shochat SJ. Ganglioside composition of human neuroblastomas. Correlation with prognosis. A Pediatric Oncology Group Study. Cancer 1985;56:2640-6
   PubMed Web of Science ®Google Scholar
• Cheung NK, Lazarus H, Miraldi FD, et al. Ganglioside GD2 specific monoclonal antibody 3F8: a phase I study in patients with neuroblastoma and malignant melanoma. J Clin Oncol 1987;5:1430-40
   PubMed Web of Science ®Google Scholar
• Cheung NK, Kushner BH, Cheung IY, et al. Anti-G(D2) antibody treatment of minimal residual stage 4 neuroblastoma diagnosed at more than 1 year of age. J Clin Oncol 1998;16:3053-60
   PubMed Web of Science ®Google Scholar
• Handgretinger R, Baader P, Dopfer R, et al. A phase I study of neuroblastoma with the anti-ganglioside GD2 antibody 14.G2a. Cancer Immunol Immunother 1992;35:199-204
   PubMed Web of Science ®Google Scholar
• Yu AL, Uttenreuther-Fischer MM, Huang CS, et al. Phase I trial of a human-mouse chimeric anti-disialoganglioside monoclonal antibody ch14.18 in patients with refractory neuroblastoma and osteosarcoma. J Clin Oncol 1998;16:2169-80
   PubMed Web of Science ®Google Scholar
• Handgretinger R, Anderson K, Lang P, et al. A phase I study of human/mouse chimeric antiganglioside GD2 antibody ch14.18 in patients with neuroblastoma. Eur J Cancer 1995;31A:261-7
   PubMed Web of Science ®Google Scholar
• Murray JL, Cunningham JE, Brewer H, et al. Phase I trial of murine monoclonal antibody 14G2a administered by prolonged intravenous infusion in patients with neuroectodermal tumors. J Clin Oncol 1994;12:184-93
   PubMed Web of Science ®Google Scholar
• Saleh MN, Khazaeli MB, Wheeler RH, et al. Phase I trial of the chimeric anti-GD2 monoclonal antibody ch14.18 in patients with malignant melanoma. Hum Antibodies Hybridomas 1992;3:19-24
   PubMedGoogle Scholar
• Saleh MN, Khazaeli MB, Wheeler RH, et al. Phase I trial of the murine monoclonal anti-GD2 antibody 14G2a in metastatic melanoma. Cancer Res 1992;52:4342-7
   PubMed Web of Science ®Google Scholar
• Barker E, Mueller BM, Handgretinger R, et al. Effect of a chimeric anti-ganglioside GD2 antibody on cell-mediated lysis of human neuroblastoma cells. Cancer Res 1991;51:144-9
   PubMed Web of Science ®Google Scholar
• Uttenreuther-Fischer MM, Huang CS, Yu AL. Pharmacokinetics of human-mouse chimeric anti-GD2 mAb ch14.18 in a phase I trial in neuroblastoma patients. Cancer Immunol Immunother 1995;41:331-8
   PubMed Web of Science ®Google Scholar
• Cheung NK, Lazarus H, Miraldi FD, et al. Ganglioside GD2 specific monoclonal antibody 3F8: a phase I study in patients with neuroblastoma and malignant melanoma. J Clin Oncol 1987;5:1430-40
   PubMed Web of Science ®Google Scholar
• Simon T, Hero B, Faldum A, et al. Consolidation treatment with chimeric anti-GD2-antibody ch14.18 in children older than 1 year with metastatic neuroblastoma. J Clin Oncol 2004;22:3549-57
   PubMed Web of Science ®Google Scholar
• Yang JC, Sherry RM, Steinberg SM, et al. Randomized study of high-dose and low-dose interleukin-2 in patients with metastatic renal cancer. J Clin Oncol 2003;21:3127-32
   PubMed Web of Science ®Google Scholar
• Weinreich DM, Rosenberg SA. Response rates of patients with metastatic melanoma to high-dose intravenous interleukin-2 after prior exposure to alpha-interferon or low-dose interleukin-2. J Immunother 2002;25:185-7
   PubMed Web of Science ®Google Scholar
• Clark JI, Atkins MB, Urba WJ, et al. Adjuvant high-dose bolus interleukin-2 for patients with high-risk renal cell carcinoma: a cytokine working group randomized trial. J Clin Oncol 2003;21:3133-40
   PubMed Web of Science ®Google Scholar
• Weil-Hillman G, Voss SD, Fisch P, et al. Natural killer cells activated by interleukin 2 treatment in vivo respond to interleukin 2 primarily through the p75 receptor and maintain the p55 (TAC) negative phenotype. Cancer Res 1990;50:2683-91
   PubMed Web of Science ®Google Scholar
• Shiloni E, Eisenthal A, Sachs D, Rosenberg SA. Antibody-dependent cellular cytotoxicity mediated by murine lymphocytes activated in recombinant interleukin 2. J Immunol 1987;138:1992-8
   PubMed Web of Science ®Google Scholar
• Bernstein NSC, Levy R. Specific enhancement of the therapeutic effect of anti-idiotype antibodies on a murine B cell lymphoma by IL-2. J Immunol 1998;140:2839-45
   Google Scholar
• Sondel PM, Hank JA, Kohler PC, et al. Destruction of autologous human lymphocytes by interleukin 2-activated cytotoxic cells. J Immunol 1986;137:502-11
   PubMed Web of Science ®Google Scholar
• Mule JJ, Yang JC, Afreniere RL, et al. Identification of cellular mechanisms operational in vivo during the regression of established pulmonary metastases by the systemic administration of high-dose recombinant interleukin 2. J Immunol 1987;139:285-94
   PubMed Web of Science ®Google Scholar
• Hank JA, Robinson RR, Surfus J, et al. Augmentation of antibody dependent cell mediated cytotoxicity following in vivo therapy with recombinant interleukin 2. Cancer Res 1990;50:5234-9
   PubMed Web of Science ®Google Scholar
• Schultz KR, Klarnet JP, Peace DJ, et al. Monoclonal antibody therapy of murine lymphoma: enhanced efficacy by concurrent administration of interleukin 2 or lymphokine-activated killer cells. Cancer Res 1990;50:5421-5
   PubMed Web of Science ®Google Scholar
• Sondel PM, Hank JA, Gan J, et al. Preclinical and clinical development of immunocytokines. Curr Opin Investig Drugs 2003;4:696-700
   PubMedGoogle Scholar
• Reisfeld RA, Gillies SD. Recombinant antibody fusion proteins for cancer immunotherapy. Curr Top Microbiol Immunol 1996;213(Pt 3):27-53
   PubMed Web of Science ®Google Scholar
• Lode HN, Xiang R, Varki NM, et al. Targeted interleukin-2 therapy for spontaneous neuroblastoma metastases to bone marrow. J Natl Cancer Inst 1997;89:1586-94
   PubMed Web of Science ®Google Scholar
• Lode HN, Xiang R, Dreier T, et al. Natural killer cell-mediated eradication of neuroblastoma metastases to bone marrow by targeted interleukin-2 therapy. Blood 1998;91:1706-15
   PubMed Web of Science ®Google Scholar
• Sondel PM, Hank JA. Combination therapy with interleukin-2 and antitumor monoclonal antibodies. Cancer J Sci Am 1997;3(Suppl 1):S121-7
   PubMed Web of Science ®Google Scholar
• Gillies SD, Young D, Lo KM, Roberts S. Biological activity and in vivo clearance of antitumor antibody/cytokine fusion proteins. Bioconjug Chem 1993;4:230-5
   PubMed Web of Science ®Google Scholar
• Gan J, Kendra K, Ricci M, et al. Specific enzyme-linked immunosorbent assays for quantitation of antibody-cytokine fusion proteins. Clin Diagn Lab Immunol 1999;6:236-42
   PubMedGoogle Scholar
• Frost JD, Hank JA, Reaman GH, et al. A phase I/IB trial of murine monoclonal anti-GD2 antibody 14.G2a plus interleukin-2 in children with refractory neuroblastoma: a report of the Children's Cancer Group. Cancer 1997;80:317-33
   PubMed Web of Science ®Google Scholar
• Albertini MR, Hank JA, Schiller JH, et al. Phase IB trial of chimeric antidisialoganglioside antibody plus interleukin 2 for melanoma patients. Clin Cancer Res 1997;3:1277-88
   PubMed Web of Science ®Google Scholar
• Hank JA, Surfus J, Gan J, et al. Treatment of neuroblastoma patients with antiganglioside GD2 antibody plus interleukin-2 induces antibody-dependent cellular cytotoxicity against neuroblastoma detected in vitro. J Immunother Emphasis Tumor Immunol 1994;15:29-37
   PubMed Web of Science ®Google Scholar
• Gillies SD, Reilly EB, Lo KM, Reisfeld RA. Antibody-targeted interleukin 2 stimulates T-cell killing of autologous tumor cells. Proc Natl Acad Sci USA 1992;89:1428-32
   PubMed Web of Science ®Google Scholar
• Weng WK, Levy R. Two immunoglobulin G fragment C receptor polymorphisms independently predict response to rituximab in patients with follicular lymphoma. J Clin Oncol 2003;21:3940-7
   PubMed Web of Science ®Google Scholar
• Voss SD, Robb RJ, Weil-Hillman G, et al. Increased expression of the interleukin 2 (IL-2) receptor beta chain (p70) on CD56+ natural killer cells after in vivo IL-2 therapy: p70 expression does not alone predict the level of intermediate affinity IL-2 binding. J Exp Med 1990;172:1101-14
   PubMed Web of Science ®Google Scholar
• Sondel PM, Kohler PC, Hank JA, et al. Clinical and immunological effects of recombinant interleukin 2 given by repetitive weekly cycles to patients with cancer. Cancer Res 1988;48:2561-7
   PubMed Web of Science ®Google Scholar
• Hank JA, Surfus JE, Gan J, et al. Activation of human effector cells by a tumor reactive recombinant anti-ganglioside GD2 interleukin-2 fusion protein (ch14.18-IL2). Clin Cancer Res 1996;2:1951-9
   PubMed Web of Science ®Google Scholar
• Sabzevari H, Gillies SD, Mueller BM, et al. A recombinant antibody-interleukin 2 fusion protein suppresses growth of hepatic human neuroblastoma metastases in severe combined immunodeficiency mice. Proc Natl Acad Sci USA 1994;91:9626-30
   PubMed Web of Science ®Google Scholar
• Becker JC, Pancook JD, Gillies SD, et al. T cell-mediated eradication of murine metastatic melanoma induced by targeted interleukin 2 therapy. J Exp Med 1996;183:2361-6
   PubMed Web of Science ®Google Scholar
• Becker JC, Varki N, Gillies SD, et al. Long-lived and transferable tumor immunity in mice after targeted interleukin-2 therapy. J Clin Invest 1996;98:2801-4
   PubMed Web of Science ®Google Scholar
• Weil-Hillman G, Fisch P, Prieve AF, et al. Lymphokine-activated killer activity induced by in vivo interleukin 2 therapy: predominant role for lymphocytes with increased expression of CD2 and leu19 antigens but negative expression of CD16 antigens. Cancer Res 1989;49:3680-8
   PubMed Web of Science ®Google Scholar
• Becker JC, Varki N, Gillies SD, et al. An antibody-interleukin 2 fusion protein overcomes tumor heterogeneity by induction of a cellular immune response. Proc Natl Acad Sci USA 1996;93:7826-31
   PubMed Web of Science ®Google Scholar
• Ozkaynak MF, Sondel PM, Krailo MD, et al. Phase I study of chimeric human/murine anti-ganglioside G(D2) monoclonal antibody (ch14.18) with granulocyte-macrophage colony-stimulating factor in children with neuroblastoma immediately after hematopoietic stem-cell transplantation: a Children's Cancer Group Study. J Clin Oncol 2000;18:4077-85
   PubMed Web of Science ®Google Scholar
• Hank J, Albertini M, Sondel P. Monoclonal antibodies, cytokines and fusion proteins in the treatment of malignant disease. Cancer Chemother Biol Response Modif 1999;18:210-22
   PubMedGoogle Scholar
• Osenga KL, Hank JA, Albertini MR, et al. A phase I clinical trial of the hu14.18-IL2 (EMD 273063) as a treatment for children with refractory or recurrent neuroblastoma and melanoma: a study of the Children's Oncology Group. Clin Cancer Res 2006;12:1750-9
   PubMed Web of Science ®Google Scholar
• Kendra K, Gan J, Ricci M, et al. Pharmacokinetics and stability of the ch14.18-interleukin-2 fusion protein in mice. Cancer Immunol Immunother 1999;48:219-29
   PubMed Web of Science ®Google Scholar
• King DM, Albertini MR, Schalch H, et al. Phase I clinical trial of the immunocytokine EMD 273063 in melanoma patients. J Clin Oncol 2004;22:4463-73
   PubMed Web of Science ®Google Scholar
• Albertini MR, Kendra K, King DM. Phase I/Ib trial of the hu14.18-IL-2 fusion protein in patients with GD2 + tumors. CTEP-UWCCC protocol #CO98901. Amendment 7, approved 1/17/02. Available on NCI-PDQ website. 2002
   Google Scholar
• Gilman AL, Ozkaynak MF, Matthay KK, et al. Phase I study of ch14.18 with granulocyte-macrophage colony-stimulating factor and interleukin-2 in children with neuroblastoma after autologous bone marrow Transplantation or stem-cell rescue: a report from the Children's Oncology Group. J Clin Oncol 2008;27(1):85-91
   PubMed Web of Science ®Google Scholar
• Xiao W, Yu A, Sorkin LS. Electrophysiological characteristics of primary afferent fibers after systemic administration of anti-GD2 ganglioside antibody. Pain 1997;69:145-51
   PubMed Web of Science ®Google Scholar
• Lammie GA, Cheung NKV, Gerald W. Ganglioside GD2 expression in the human nervous system and in neuroblastomas-an immunohistochemical study. Int J Oncol 1993;3:909-15
   PubMed Web of Science ®Google Scholar
• Neal ZC, Yang JC, Rakhmilevich AL, et al. Enhanced activity of hu14.18-IL2 immunocytokine against murine NXS2 neuroblastoma when combined with interleukin 2 therapy. Clin Cancer Res 2004;10:4839-47
   PubMed Web of Science ®Google Scholar
• Foon KA, Sen G, Hutchins L, et al. Antibody responses in melanoma patients immunized with an anti-idiotype antibody mimicking disialoganglioside GD2. Clin Cancer Res 1998;4:1117-24
   PubMed Web of Science ®Google Scholar
• Batova A, Kamps A, Gillies SD, et al. The Ch14.18-GM-CSF fusion protein is effective at mediating antibody-dependent cellular cytotoxicity and complement-dependent cytotoxicity in vitro. Clin Cancer Res 1999;5:4259-63
   PubMed Web of Science ®Google Scholar
• Bogner MP, Voss SD, Bechhofer R, et al. Serum CD25 levels during interleukin-2 therapy: dose dependence and correlations with clinical toxicity and lymphocyte surface sCD25 expression. J Immunother 1991,1992;11:111-8
   Web of Science ®Google Scholar
• Voss SD, Hank JA, Nobis CA, et al. Serum levels of the low-affinity interleukin-2 receptor molecule (TAC) during IL-2 therapy reflect systemic lymphoid mass activation. Cancer Immunol Immunother 1989;29:261-9
   PubMed Web of Science ®Google Scholar
• Shusterman S, London WB, Gillies SD, et al. Anti-neuroblastoma activity of hu14.18-IL2 against minimal residual disease in a Children's Oncology Group (COG) phase II study. J Clin Oncol 2008;26(May 20 Suppl.): abstract 9039
   Google Scholar
• Albertini MR, Hank JA, Schalch H, et al. Phase II trial of hu14.18-IL2 (EMD 273063) for patients with metastatic melanoma. J Clin Oncol 2008;26(May 20 Suppl.): abstract 3002
   Google Scholar
• Johnson EE, Lum HD, Rakhmilevich AL, et al. Intratumoral immunocytokine treatment results in enhanced antitumor effects. Cancer Immunol Immunother 2008;57:1891-902
   PubMed Web of Science ®Google Scholar
• Imboden M, Murphy KR, Rakhmilevich AL, et al. The level of MHC class I expression on murine adenocarcinoma can change the antitumor effector mechanism of immunocytokine therapy. Cancer Res 2001;61:1500-7
   PubMed Web of Science ®Google Scholar
• Neal ZC, Imboden M, Rakhmilevich AL, et al. NXS2 murine neuroblastomas express increased levels of MHC class I antigens upon recurrence following NK-dependent immunotherapy. Cancer Immunol Immunother 2004;53:41-52
   PubMed Web of Science ®Google Scholar
• Neal ZC, Sondel PM, Bates MK, et al. Flt3-L gene therapy enhances immunocytokine-mediated antitumor effects and induces long-term memory. Cancer Immunol Immunother 2007;56:1765-74
   PubMed Web of Science ®Google Scholar
• van V, Beijersbergen RL, Bernards R. N-myc suppresses major histocompatibility complex class I gene expression through down-regulation of the p50 subunit of NF-kappa B. EMBO J 1993;12:195-200
   PubMed Web of Science ®Google Scholar